ATOS Stock Overview
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases.
Atossa Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.28|
|52 Week High||US$9.80|
|52 Week Low||US$0.81|
|1 Month Change||-11.28%|
|3 Month Change||-35.41%|
|1 Year Change||31.03%|
|3 Year Change||100.00%|
|5 Year Change||-90.87%|
|Change since IPO||-99.74%|
Recent News & Updates
Atossa Therapeutics: Diversification Into COVID Makes Sense In A Variants World
Atossa Therapeutics is clinical-stage biotech whose stock has trended a highly volatile path during the last one-year period. In addition to breast cancer research, where the company has been involved for years, it also focuses on producing nasal drops and inhalation therapy for combating COVID-19. Despite so many vaccines being available, alternatives still make sense in view of the coronavirus mutating rapidly and the limited immunity period conferred by current ones. There is sufficient cash to fund steadily rising R&D expenses. Currently below the $4 level, with its proprietary compounds constituting valuable assets, the company makes for investment in this COVID world.
Atossa Therapeutics (NASDAQ:ATOS) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Atossa Therapeutics: Hope Springs Eternal
After a blistering June rally, we see a temporary top here probably back to around the $4 level. Implied volatility remains significantly elevated. We are going to get our move sooner rather than later. We are controlling risk by rolling puts out in time. Significant upside potential due to recent results remains.
Atossa Therapeutics to be included in the Russell 2000, 3000 indexes
Atossa Therapeutics (ATOS) is set to be added to the Russell 2000 and Russell 3000 Indexes, effective after the U.S. market opens on June 28, 2021. “Atossa’s inclusion in both the Russell 2000 and Russell 3000 Indexes present an important opportunity for us to further expand Atossa’s awareness among a broader group of investors, which we expect will also further enhance its liquidity,” said Kyle Guse, Atossa’s CFO and General Counsel.
|ATOS||US Biotechs||US Market|
Return vs Industry: ATOS exceeded the US Biotechs industry which returned 5.3% over the past year.
Return vs Market: ATOS exceeded the US Market which returned 21.3% over the past year.
|ATOS Average Weekly Movement||8.8%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.0%|
|10% least volatile stocks in US Market||2.3%|
Stable Share Price: ATOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ATOS's weekly volatility has decreased from 20% to 9% over the past year.
About the Company
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines in the areas of oncology and infectious diseases. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; AT-H201, a drug candidate to improve lung function in COVID-19 patients; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer.
Atossa Therapeutics Fundamentals Summary
|ATOS fundamental statistics|
Is ATOS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATOS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.22|
|Net Profit Margin||0.00%|
How did ATOS perform over the long term?See historical performance and comparison
Is Atossa Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATOS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATOS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ATOS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATOS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATOS is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.9x).
How is Atossa Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATOS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ATOS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ATOS's is expected to become profitable in the next 3 years.
Revenue vs Market: ATOS is forecast to have no revenue next year.
High Growth Revenue: ATOS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATOS's Return on Equity is forecast to be high in 3 years time
How has Atossa Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATOS is currently unprofitable.
Growing Profit Margin: ATOS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATOS is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.
Accelerating Growth: Unable to compare ATOS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATOS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: ATOS has a negative Return on Equity (-16.45%), as it is currently unprofitable.
How is Atossa Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ATOS's short term assets ($143.0M) exceed its short term liabilities ($1.7M).
Long Term Liabilities: ATOS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: ATOS is debt free.
Reducing Debt: ATOS has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATOS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ATOS has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.8% each year
What is Atossa Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATOS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATOS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATOS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve Quay (70 yo)
Dr. Steven C. Quay, also known as Steve, M.D., Ph D., FCAP, has been the Chief Executive Officer and President of Atossa Therapeutics, Inc. (formerly known as Atossa Genetics Inc.) since April 30, 2009 and...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: ATOS's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: ATOS's board of directors are seasoned and experienced ( 10 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1106.8%.
Atossa Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Atossa Therapeutics, Inc.
- Ticker: ATOS
- Exchange: NasdaqCM
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$288.703m
- Shares outstanding: 126.62m
- Website: https://www.atossatherapeutics.com
Number of Employees
- Atossa Therapeutics, Inc.
- 107 Spring Street
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/28 23:03|
|End of Day Share Price||2021/11/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.